Combination Therapy Should Be Reserved as Second-Line Treatment of Onychomycosis: A Systematic Review of Onychomycosis Clinical Trials

Julianne M. Falotico 1, Rebecca Lapides 2 and Shari R. Lipner 3,*

1 Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794, USA; julianne.falotico@stonybrookmedicine.edu
2 Robert Larner, M.D. College of Medicine at the University of Vermont, Burlington, VT 05405, USA; rebecca.lapides@med.uvm.edu
3 Weill Cornell Medicine, Department of Dermatology, New York, NY 10021, USA
* Correspondence: shl9032@med.cornell.edu; Tel.: +1-646-962-3376

Abstract: Onychomycosis is the most common nail disease encountered in clinical practice. Its importance extends well beyond aesthetics, often causing pain, difficulty with ambulation and performing daily activities, and impairing quality of life. Many patients fail to achieve cure with antifungal monotherapy and recurrences are common. Combination therapy has therefore gained considerable interest, given the potential for drug synergy and prevention of antifungal resistance, but it has not been well studied. A systematic review of onychomycosis medication only, as well as medication and procedural (laser, debridement, photodynamic therapy), clinical or randomized controlled trials evaluating combination vs. monotherapies was performed. After exclusions, 30 studies were included in the final analysis. There were conflicting results for medication-only trials, with some showing significant benefit of combination therapy over monotherapy, however, trials were not robustly designed and lacked sufficient follow-up. Procedural studies also lacked long-term follow-up, and failed to demonstrate efficacy in some severe onychomycosis cases. Considering the high cure rates demonstrated in pivotal antifungal monotherapy trials, and conflicting results, costs, and safety concerns associated with combination therapy, we recommend that combination therapy be reserved as second-line treatment options in patients with poor prognostic factors or for those who failed monotherapy for onychomycosis.

Keywords: onychomycosis; nail disease; fungal nail infection; randomized controlled trial; clinical trial; combination therapy; monotherapy

1. Introduction

Onychomycosis is a fungal nail infection due to dermatophytes, onychomycosis, and yeast [1], clinically presenting with nail plate onycholysis, thickening, and subungual hyperkeratosis [2], with significant physical, aesthetic, and psycho-social consequences. Currently, oral terbinafine, itraconazole, and griseofulvin, as well as topical ciclopirox, efinaconazole, and tavaborole, are United States (US) Food and Drug Administration (FDA) approved for onychomycosis treatment, and oral fluconazole is often used off-label [3,4]. In a systematic review and meta-analysis of 26 randomized controlled trials (RCT) investigating systemic monotherapy for toenail onychomycosis [5], there was a significantly greater odds ratio (OR) of achieving mycological cure for all monotherapy treatments vs. placebo. Onychomycosis treatment is challenging, and is individualized based on disease severity, comorbidities, and infecting organism(s), with consideration of associated medication adverse events, drug–drug interactions, and cost [1,6]. Some disadvantages of onychomycosis monotherapy include potential antifungal resistance, and difficulty of achieving high concentrations of biologically effective drug in affected...
nails, particularly in severe cases of onychomycosis [7]. In a five-year, blinded follow-up study of patients achieving mycological cure at 12 months following oral terbinafine or itraconazole monotherapy treatment, 23% and 53% of patients, respectively, experienced mycological relapse or reinfection [8]. Therefore, there is a need for studies with long term follow-ups to track recurrences after complete cures to optimize treatments regimens and prevent recurrences.

Combinations of oral medications, topical medications, and devices, have been considered in cases where there are expected poor responses to monotherapy, greater than 50–60% nail involvement, or more than three affected nails [4,9,10]. Parallel, or simultaneous, combination therapy is recommended in patients likely to fail therapy (i.e., with underlying comorbidities such as diabetes), while sequential therapy is recommended in patients with poor responses to initial treatment [11]. It is theorized that combination therapy allows for antimicrobial synergy, broader antifungal coverage with increased fungicidal activity, and decreased resistance [12], as well as improved clinical cures when using drugs with different mechanisms of action or administration routes [13]. However, research on combination antifungal therapy for onychomycosis is sparse and the most recent reviews date from 1999–2006 [7,11–16]. In this systematic review, we examine clinical trials comparing combination vs. monotherapy for onychomycosis treatment, to guide clinical management.

2. Materials and Methods

The objective of this systematic review was to examine combination therapy for onychomycosis treatment, and is reported in accordance with PRISMA guidelines [17]. This review was not registered and a protocol was not prepared. PubMed, Scopus, and Web of Science databases were searched for articles on onychomycosis combination therapy on 1 July 2021, for all peer-reviewed, English-language, human subject onychomycosis clinical and RCTs with no date ranges, and using search terms “onychomycosis treatment”, “onychomycosis therapy”, and “onychomycosis combination therapy”. Articles were independently screened by two authors (R.L. and S.R.L.) based on abstracts. Both authors then independently reviewed full-text articles for eligibility and extracted data for eligible studies. Inclusion required investigation of a combination therapy versus monotherapy for onychomycosis treatment, and mycological confirmation with microscopy, culture, or another validated laboratory-based testing method prior to treatment initiation. Duplicate, non-English, non-randomized, non-clinical trials, and studies investigating monotherapy treatment regimens, diagnoses other than onychomycosis (i.e., tinea pedis), lacking monotherapy control groups, or control group medications that differed from both drugs in the combination group were excluded. Outcomes, including number of subjects, treatment protocol, treatment success rate, and adverse effects, were extracted from each study. Data that was not available was stated (N/A). The PRISMA flow diagram (Figure 1) provides additional information regarding the systematic search.
3. Results

There was a total of 726 studies from the initial search, with 30 clinical trials (2531 participants) meeting inclusion criteria and included in the final analysis (Figure 1). Half (15/30) of the studies investigated medications only (Table 1) and half studied procedures (debridement, photodynamic therapy, lasers) in combination with medication (Table 2).
### Table 1. Treatment protocols and outcomes for studies investigating medication-only based combination therapies for onychomycosis treatment.

| Study | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Combination Therapy Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-------|---------------------|----------------------|-------------------------------|------------------------------------------|---------------------------------|--------------------------------|--------------------------------|-------------------------------|----------------------------------|----------------------------------|
| Hay, R. J. et al., 1987 [18] † | Oral griseofulvin & topical tioconazole | 10                   | Oral griseofulvin 1 g daily + topical tioconazole 28% on 1 affected side × 12 months | Oral griseofulvin 1 g daily + placebo on other affected side × 12 months | 12 months CO: 69 | 12 months CO: 41 | p < 0.005 * | N/a | 1, 20 |
| Friedman-Birnbaum, R., et al., 1997 [19] † | Oral griseofulvin & topical bifonazole | 98                   | Oral griseofulvin 500 mg daily + topical bifonazole 1% cream × 4 weeks | Oral griseofulvin 500 mg daily + placebo × 4 weeks | 4 months M: 93 | 4 months M: 66 | M: p < 0.01 * | RL: p < 0.01 * | 5, 8.5 | 1, 1.7 |
| Baran, R. et al., 2000 [20] † | Oral terbinafine & topical amorolfine | 145                  | Topical amorolfine 5% once weekly × 15 months plus oral terbinafine 250 mg daily × 6 weeks (AT6) or 12 weeks (AT12) | Oral terbinafine 250 mg daily × 12 weeks (T12) | 3 months M: 35 (AT6), 27.5 (AT12) | 3 months M: 17.1 | M: p < 0.001 * | C: p < 0.04 * | CO: p = 0.03 * | AT6: 21, 42 | AT12: 23, 49 | 23, 48 |
| Baran, R. 2001 [21] † | Oral terbinafine & topical amorolfine | 145                  | Topical amorolfine 5% once weekly × 15 months plus oral terbinafine 250 mg daily × 6 weeks (AT6) or 12 weeks (AT12) | Oral terbinafine 250 mg daily × 12 weeks (T12) | 3 months M: 35 (AT6), 27.5 (AT12) | 3 months M: 17.1 | M: p < 0.001 * | C: p < 0.04 * | CO: p = 0.03 * | Not specified by group (n = 34 total) | Not specified by group (n = 34 total) |
| Baran, R. et al., 2007 [22] † | Oral terbinafine & topical amorolfine | 208                  | Oral terbinafine 250 mg daily × 3 months + amorolfine hydrochloride 5% nail lacquer once weekly × 12 months | Oral terbinafine 250 mg daily × 3 months | 3 months M: 94.2 | 3 months M: 59.7 | M: p < 0.001 * | C: p < 0.04 * | CO: p = 0.03 * | 19, 15.9 | 15, 11.6 |
Table 1. Cont.

| Study                                      | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|--------------------------------------------|---------------------|----------------------|--------------------------------|--------------------------------|--------------------------------|---------------------------------|--------------------------------------|----------------------------------------|----------------------------------------|
| Avner, S. et al., 2005 [23] †             | Oral terbinafine & topical ciclopirox | 68                   | Oral terbinafine 250 mg daily × 16 weeks + topical ciclopirox nail lacquer daily × 9 months | Oral terbinafine 250 mg daily × 16 weeks | 9 months M: 88.2 CO: 67.7 CS: 82.4 | 9 months M: 64.7 CO: 50 CS: 58.8 | M: p = 0.043 * CO: p = 0.218 N: p = 0.004 * | N/a                                    | N/a                                    |
| Gupta, A. K. et al., 2005 [24]            | Oral terbinafine & topical ciclopirox | 63                   | Pulse: oral terbinafine 250 mg × 4 weeks, 4-week rest, 4-weeks on + ciclopirox nail lacquer daily × 48 weeks Continuous: oral terbinafine 250 mg daily × 12 weeks + ciclopirox nail lacquer daily × 48 weeks | Oral terbinafine 250 mg daily × 12 weeks | 48 weeks M: 66.7 (pulse), 70.4 (continuous) E: 40.0 (pulse), 33.3 (continuous) | 48 weeks M: 56.0 E: 34.8 | M: p > 0.05 E: p > 0.05 | 4.3, 20.5 (pulse), 5.8, 21.4 (continuous) | 5.5, 22.0                              |
| Jaiswal, A. et al., 2007 [25]             | Oral terbinafine & topical ciclopirox or amorolfine | 92                   | (A) Oral terbinafine pulse therapy + topical ciclopirox olamine 8% once daily × 4 months (B) Oral terbinafine pulse therapy + topical amorolfine hydrochloride 5% once weekly × 4 months | Oral terbinafine 250 mg twice daily × 7 days for 4 months (pulse therapy) | 9 months C: 82.6 (A), 73.91 (B) M: 83.3 (A), 70 (B) | 9 months C: 71.73 M: 82.6 | C: p > 0.05 M: p > 0.05 | Not specified by group (n = 14 total) | Not specified by group (n = 14 total) |
| Study | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-------|---------------------|----------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-----------------------------|------------------------------------------|------------------------------------------|
| Tietz, H. J. et al., 2013 [26] † | Topical bifonazole & urea | 595 | Nail detachment with urea 40% paste applied daily for 14–28 days + topical bifonazole 1% applied daily × 28 days | Nail detachment with urea 40% paste applied daily for 14–28 days + topical placebo cream applied daily × 28 days | 2 weeks: CO: 54.8, M: 64.5, C: 86.6 3 months: CO: 50.7, M: 61.5, C: 73.8 6 months: CO: 33.6, M: 52.1, C: 56.8 | 2 weeks: CO: 42.2, M: 49.0, C: 82.8 3 months: CO: 40.9, M: 49.1, C: 73.7 6 months: CO: 34.6, M: 48.1, C: 56.8 | 2 weeks: CO: p = 0.0024 *, M: p = 0.0001 *, C: p = 0.2109 3 months: CO: p = 0.0260 *, M: p = 0.0033 *, C: p = 1.0 | Treatment phase: 12, 3.7 Follow-up: 35, 10.8 | Treatment phase: 18, 5.5 Follow-up: 43, 13.1 |
| Bassiri-Jahromi et al., 2012 [27] | Topical fluconazole & urea | 66 | Topical fluconazole 1% + urea 40% once daily × 6 months | Topical fluconazole 1% once daily × 6 months | 6 months: M: 82.8, CR: 77.1 | 6 months: M: 62.6, CR: 68 | Not reported | Not specified by group (n = 1 total) | Not specified by group (n = 1 total) |
| Lecha, M. 2001 [28] † | Oral itraconazole & topical amorolfine | 114 | Amorolfine 5% nail lacquer once weekly × 24 weeks + oral itraconazole 200 mg daily × 6 weeks (A) or 12 weeks (B) | Oral itraconazole 250 mg daily × 12 weeks | 12 weeks: M: 93.3 (A), 82.9 (B) 24 weeks: M: >90 (A & B) C: 88.1 (A), 100 (B) CO: 83.7 (A), 93.9 (B) | 12 weeks: M: 41.2 24 weeks: M: >69 C: 90.3 CO: 68.8 | 12 weeks: M: p < 0.001 * (A & B vs. monotherapy) 24 weeks: M: p < 0.001 * (A & B vs. monotherapy) | Not specified by group (n = 21 total) | Not specified by group (n = 21 total) |
Table 1. Cont.

| Study | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-------|---------------------|---------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-----------------------------|---------------------------------|---------------------------------|
| Rigopoulos, D. et al., 2003 [29] | Oral itraconazole & topical amorolfine | 85 | Oral itraconazole 400 mg daily $\times$ 1 week at 3-week intervals (pulse therapy) $\times$ 2 months + topical amorolfine 5% solution nail lacquer once weekly $\times$ 6 months | Oral itraconazole $\times$ 3 pulses | 3 months | 3 months | M: 74 9 months CO: 93 | M: 60 9 months CO: 91 | M: $p > 0.1$ CO: $p > 0.1$ | N/a N/a |
| Gupta, A. K. et al., 2001 [30] † | Oral itraconazole & terbinafine | 165 | Two pulses oral itraconazole (200 mg twice daily $\times$ 1 week) + 1 or 2 pulses oral terbinafine (250 mg twice daily $\times$ 1 week) | Three or four pulses oral terbinafine | 72 weeks | 72 weeks | M: 66.7 C: 51.9 CO: 48.1 E: 60.5 | M: 46.3 C: 36.8 CO: 30.5 E: 43.2 | M: $p = 0.007$ * C: $p = 0.09$ CO: $p = 0.03$ * E: $p = 0.02$ * | 12, 16.0 22, 24.4 |
| Gupta, A. K. et al., 2013 [31] | Oral itraconazole & terbinafine | 149 | Oral itraconazole 200 mg daily for weeks 1–4 & oral terbinafine 250 mg daily for weeks 3–6 | (A) Oral terbinafine 250 mg daily $\times$ 12 weeks (B) Oral terbinafine 250 mg/day 4 weeks on, 4 weeks off, 4 weeks on (C) Oral itraconazole 200 mg twice daily pulse therapy (7 days on, 21 days off) $\times$ 3 pulses | After 48 weeks | After 48 weeks | MR: 57 | MR: $p = 0.085$ R: 67 | MR: $p = 0.711$ | N/a N/a |
### Table 1. Cont.

| Study | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-------|---------------------|----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Arenas, et al., 1991 [32] | Oral itraconazole or griseofulvin & topical isoconazole or urea | 83                   | Oral griseofulvin 500 mg daily + topical isoconazole 1% twice daily (A) or urea 40% occlusive patch (B) × 6 months | Topical placebo cream + oral griseofulvin 500 mg daily (E) or oral itraconazole 100 mg daily (F) × 6 months | 6 months M: (A) 46.1 (B) 42.8 (C) 73.3 (D) 78.5 Overall itraconazole (C, D, F): 80.48 | 6 months M: (E) 26.6 (F) 91.65 | 6 months: p = 0.010 Overall M (griseofulvin vs. itraconazole): p = 0.001 * | N/a                             | N/a                             |

C: clinical cure rate; CI: confidence interval; CO: complete cure rate; CR: clinical improvement rate; CS: clinical status, marked improvement or cured; E: effective therapy rate; M: mycological cure rate; MR: mycological recurrence rate; N/a: not applicable; R: recurrence rate; RL: relapse rate. * Significant difference between treatment groups. † Studies showing significant benefit of combination therapy over monotherapy.

### Table 2. Treatment protocols and outcomes for studies investigating procedures (debridement, photodynamic therapy, or lasers) in combination with medication for onychomycosis treatment.

| Study | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-------|---------------------|----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Zhang, J. et al., 2016 [33] † | Laser & topical amorolfine | 9                   | 2940-nm fractional Er:YAG laser once weekly at weeks 1, 2, 3, 4, 8, & 12 + 5% amorolfine lacquer twice weekly × 12 weeks | Amorolfine 5% lacquer twice weekly × 12 weeks | 12 weeks M: 70 24 weeks M: 75 | 12 weeks M: 25 24 weeks M: 20 | 12 weeks: p = 0.01 * 24 weeks: p = 0.001 * | Not specified by group (n = 3 total) | Not specified by group (n = 3 total) |
| Study | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-------|---------------------|---------------------|-------------------------------|--------------------------------|-------------------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|
| Bunyaratevej, S. et al., 2020 [34]† | Laser & topical amorolfine | 60 | (A) Long-pulsed Nd:YAG 1064-nm laser × 4 sessions at 1 month intervals + topical amorolfine nail lacquer × 3 months | (B) Nd:YAG 1064-nm laser × 4 sessions at 1 month intervals | Combination (C) Topical amorolfine nail lacquer × 3 months | 3 months | M: 65 C: 30 | 3 months | M: 35 (B), 60 (C) C: 10 (B), 30 (C) | M: $p = 0.05$ * (A vs. B) N/a N/a |
| Zhang, J. et al., 2021 [35]† | Laser & topical amorolfine | 78 | 2940-nm Er:YAG fractional laser × 6 treatments at weeks 1, 2, 3, 4, 8, & 12 + topical amorolfine 5% nail lacquer twice weekly × 12 weeks | Topical amorolfine 5% nail lacquer twice weekly × 12 weeks | Mild (A), moderate (B), severe (C) onychomycosis 12 weeks | M: 100 (A), 63.64 (B), 7.69 (C) O: 2 (A), 6 (B), 4 (C) 24 weeks | M: 84.62 (A), 38.24 (B), 8.33 (C) O: 1 (A), 3 (B), 7 (C) 24 weeks | 12 weeks | M: $p = 0.038$ * (B) O: $p = 0.037$ * (A), $p < 0.001$ * (B) 24 weeks | M: $p = 0.046$ * (A), $p = 0.01$ * (B) O: $p = 0.002$ * (A), $p < 0.001$ * (B) 32, 84.213 N/a |
| Study                        | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-----------------------------|---------------------|----------------------|-------------------------------|--------------------------------|-------------------------------|-------------------------------|-------------------------------|-----------------------------------------|----------------------------------------|
| Bonhert, K. et al., 2019 [36] † | Laser & topical efinaconazole | 30                   | 1064-nm Nd:YAG laser × 6 treatments spaced 4 weeks apart + topical efinaconazole 10% once daily × 48 weeks | Topical efinaconazole 10% once daily × 48 weeks | 48 weeks M: 90 | 48 weeks M: 70 | Combined vs. monotherapy: | - Quicker overall improvement at weeks 24 ($p = 0.04^*$), 36, 48 (both $p = 0.03^*$), and 52 ($p = 0.02^*$) | - Greater improvement in SCIO index at weeks 36, 48 (both $p = 0.04^*$), & 52 ($p = 0.02$) | 7, 46% N/a |
| Li, Y. et al., 2016 [37] † | Laser & oral itraconazole | 19                   | 1064-nm Nd:YAG laser once weekly × 8 weeks + 200 mg oral itraconazole twice daily × 1 week for 4 times | 1064-nm Nd:YAG laser once weekly × 8 weeks for 4 times | Mild/moderate (A), severe onychomycosis (B) 8 weeks E: 21 (A), 20 (B) 16 weeks E: 20 (A), 19 (B) 24 weeks E: 19 (A), 21 (B) | Mild/moderate (A), severe onychomycosis (B) 8 weeks E: 17 (A), 13 (B) 16 weeks E: 17 (A), 14 (B) 24 weeks E: 19 (A), 11(B) | A: $p > 0.05$ (8, 16, 24 weeks) | B: $p < 0.05^*$ (8 & 24 weeks), $p > 0.05$ (16 weeks) | N/a N/a |
| Study | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-------|---------------------|---------------------|-------------------------------|------------------------------|-------------------------------|--------------------------------|-----------------------------|----------------------------------------|----------------------------------------|
| Hamed Khater, M. & Khattab, F.M. 2020 [38] † | Laser & oral itraconazole | 30 | 1064-nm long-pulsed Nd-YAG laser × 6 sessions (every 2 weeks × 3 months) + oral itraconazole 200 mg twice daily 1 week per month × 3 months | Oral itraconazole 200 mg twice daily 1 week per month × 3 months | C: Excellent: 66.6 Moderate: 6.6 Good: 20.1 Mild: 6.6 MR: Excellent: 13.3 Moderate: 40.1 Good: 13.3 Mild: 33.3 Mean OSI after treatment: 5.07 ± 4.15 | C: Excellent: 13.3 Moderate: 33.3 Good: 40.1 Mild: 13.3 MR: Excellent: 13.3 Moderate: 40.1 Good: 13.3 Mild: 33.3 Mean OSI after treatment: 6.67 ± 3.60 | Overall C: p < 0.001 * Mean OSI: p < 0.01 * | N/a | N/a |
| Zaki, A.M. et al., 2020 [39] † | Laser & topical tioconazole | 120 | Fractional CO2 laser × 5 sessions at 3-week intervals + topical tioconazole 28% applied twice daily × 16 weeks | (A) Fractional CO2 laser × 5 sessions at 3-week intervals × 16 weeks (B) Topical tioconazole 28% applied twice daily × 16 weeks | C: 55 PS: 60 KOH turned negative: 80 Culture turned negative: 70 | C: 30 (A), 25 (B) PS: 40 (A), 30 (B) KOH turned negative: 60 (A), 55 (B) Culture turned negative: 50 (B), 30 (C) | C: p < 0.001 * PS: p = 0.007 * KOH turned negative: p < 0.001 * Culture turned negative: p < 0.001 * | N/a | N/a |
| Zhou, B.R. et al., 2016 [40] † | Laser & topical luliconazole | 60 | Fractional CO2 laser × 12 sessions at 2-week intervals + luliconazole 1% cream daily × 6 months | Fractional CO2 laser × 12 sessions at 2-week intervals × 6 months | 3 months C: 69.6 6 months C: 73.0 | 3 months C: 50.9 6 months C: 52.8 | C: p = 0.004 * (3 months), p = 0.002 * (6 months) M: p = 0.006 * | N/a | N/a |
| Study                        | Combination Therapy                                      | # Subjects Completed | Combination Treatment Protocol                                                                                     | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-----------------------------|----------------------------------------------------------|----------------------|------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|-------------------------------|-----------------------------------|-------------------------------------|-------------------------------------|
| Xu, Y. et al., 2014 [41] †  | Laser & oral terbinafine                                  | 53                   | Long-pulsed 1064-nm Nd:YAG laser treatment once weekly + oral terbinafine 250 mg daily × 24 weeks                  | (A) Long-pulsed 1064-nm Nd:YAG laser treatment once weekly × 24 weeks (B) Oral terbinafine 250 mg daily × 24 weeks | 4 weeks                        | M: 0 (A), 10 (B)                   | C: 0 (A), 0 (B)                      | 8 weeks                             | M: 16.13 (A), 36.67 (B)            | (B) C: 3.23 (A), 16.67 (B)          |
|                             |                                                          |                      |                                                                                                                |                                |                                | M: C 12 weeks                     | M: 35.48 (A), 70 (B)               | C: 29.03 (A), 63.33 (B)              | M: C p < 0.005 * (combination vs. A & B): p < 0.05 * (all timepoints) |
|                             |                                                          |                      |                                                                                                                |                                |                                | M: C 24 weeks                     | M: 35.48 (A), 70 (B)               | C: 29.03 (A), 63.33 (B)              | M: C p < 0.005 * (combination vs. A & B): p < 0.05 * (all timepoints) |
|                             |                                                          |                      |                                                                                                                |                                |                                | M: C 24 weeks                     | M: 77.42 (A), 83.33 (B)             | C: 64.52 (A), 73.33 (B)              | M: C p < 0.005 * (combination vs. A & B): p < 0.05 * (all timepoints) |
| Kim, T.I. et al., 2016 [42] † | Laser & topical naftifine HCl spray                       | 53                   | 1064-nm Nd:YAG laser × 3 sessions at 4-week intervals + topical naftifine HCl spray daily × 24 weeks             | (A) 1064-nm Nd:YAG laser × 3 sessions at 4-week intervals (B) Naftifine HCl spray daily × 24 weeks | 12 weeks                        | C: 35.2                         | M: 14.1                           | 24 weeks                           | C: 25.3 (A), 7.5 (B)                 | (B) M: 8.9 (A), 6.0 (B)              |
|                             |                                                          |                      |                                                                                                                |                                |                                | M: C 24 weeks                     | M: 40.8                           | C: 15.2 (A), 4.5 (B)                | M: C p < 0.005 * (combination vs. A & B): p < 0.05 * (all timepoints) |
| Study                        | Combination Therapy                                                                 | # Subjects Completed | Combination Therapy Protocol                                                                 | Monotherapy Treatment Protocol                      | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|------------------------------|--------------------------------------------------------------------------------------|----------------------|------------------------------------------------------------------------------------------------|---------------------------------------------------|--------------------------------|---------------------------------|----------------------------------|------------------------------------------|----------------------------------------|
| Gilaberte, Y. et al., 2017   | Methyl aminolevulinate photodynamic therapy & topical urea                           | 40                   | Methyl aminolevulinate photodynamic therapy + urea 40% ointment × 3 sessions                   | Placebo (red light) photodynamic therapy + urea 40% ointment × 3 sessions | M: 31.82                        | M: 11.1                        | M: p = 0.178                     | Pigmentation: 22, 100                  | Pigmentation: 15, 83.3                 |
|                             |                                                                                     |                      |                                                                                               |                                                   | CO: 18.18                      | CO: 31.82                      | CO: p = 0.23                    | Inflammation: 4, 18.2                | Inflammation: 0, 0                    |
|                             |                                                                                     |                      |                                                                                               |                                                   |                                |                                 |                                 | Tinea pedis: 3, 13.64              | Tinea pedis: 2, 11.1                 |
| Jennings, M.B. et al., 2006  | Debridement & oral terbinafine                                                      | 504                  | Oral terbinafine 250 mg daily × 12 weeks + aggressive nail debridement                        | Oral terbinafine 250 mg daily × 12 weeks          | 48 weeks                       | 48 weeks                       | C: p = 0.023 *                    | Not specified by group              | Not specified by group              |
|                             |                                                                                     |                      |                                                                                               |                                                   | C: 59.8                        | C: 51.4                        |                                 | (n = 116 total)                    | (n = 116 total)                      |
|                             |                                                                                     |                      |                                                                                               |                                                   | M: 67.5                        | M: 62.6                        |                                 |                                 |                                 |
|                             |                                                                                     |                      |                                                                                               |                                                   | CO: 37.8                       | CO: 32.5                       |                                 |                                 |                                 |
|                             |                                                                                     |                      |                                                                                               |                                                   |                                |                                 |                                 |                                 |                                 |
| Potter, L.P. et al., 2007    | Debridement & oral terbinafine                                                      | 504                  | Oral terbinafine 250 mg daily × 12 weeks + aggressive nail debridement at baseline & weeks 6, 12, & 24 | Oral terbinafine 250 mg daily × 12 weeks          | SF: 28.7                        | SF: 25.8                        | SF: p = 0.0395 *                 | N/a                                    | N/a                                    |
|                             |                                                                                     |                      |                                                                                               |                                                   | SB: 20.4                       | SB: 19.2                        |                                 |                                 |                                 |
|                             |                                                                                     |                      |                                                                                               |                                                   | A: 25.5                         | A: 23.4                         |                                 |                                 |                                 |
|                             |                                                                                     |                      |                                                                                               |                                                   | PA: 20.7                        | PA: 20.7                        |                                 |                                 |                                 |
|                             |                                                                                     |                      |                                                                                               |                                                   | OP: 28.2                        | OP: 28.2                        |                                 |                                 |                                 |
|                             |                                                                                     |                      |                                                                                               |                                                   | S: 8.9                          | S: 10.0                         |                                 |                                 |                                 |
| Malay, D.S. et al., 2009     | Debridement & topical ciclopirox                                                    | 55                   | Debridement at 3-month intervals × 9–12 months + topical ciclopirox 8% daily                  | Debridement at 3-month intervals × 9–12 months    | M: 76.74                        | M: 0                            | M: p < 0.05 *                    | N/a                                    | N/a                                    |
|                             |                                                                                     |                      |                                                                                               |                                                   |                                |                                 |                                 |                                 |                                 |
Table 2. Cont.

| Study | Combination Therapy | # Subjects Completed | Combination Treatment Protocol | Monotherapy Treatment Protocol | Combination Treatment Rates, % | Monotherapy Treatment Rates, % | Difference between Groups | Adverse Effects Combination Therapy, n, % | Adverse Effects Monotherapy, n, % |
|-------|---------------------|---------------------|--------------------------------|--------------------------------|-------------------------------|-------------------------------|-------------------------------|--------------------------------|--------------------------------|
| Shemer, A. et al., 2016 [47] † | Nail drilling, oral & topical terbinafine | 98 | (A) Nail drilling once at baseline + oral terbinafine 250 mg daily × 2 weeks + topical terbinafine 1% spray twice daily × 6 months | 10 weeks M: 14.3 (A), 2.4 (B) 16 weeks M: 35.7 (A), 6.3 (B) CN: 63.75 (A), 39.95 (B) 22 weeks M: 46.2 (A), 32.4 (B) CN: 59.38 (A), 52.39 (B) 28 weeks M: 47.1 (A), 34.2 (B) | 10 weeks M: 0.0 16 weeks M: 0.0 CN: 31.36 22 weeks M: 5.0 CN: 23.81 28 weeks M: 8.0 | Not specified by group (n = 8 total) | Not specified by group (n = 8 total) | 16 weeks CN: p = 0.028 * (A vs. C) 22 weeks CN: p = 0.005 * (A vs. C), p = 0.014 * (B vs. C) | Not specified by group (n = 8 total) | Not specified by group (n = 8 total) |

A: appearance problems; C: clinical cure rate; CI: confidence interval; CN: mean percent clear nail; CO: complete cure rate; CR: clinical response rate; D: mean diameter of inhibition zone (mm); E: efficacy rate; HCl: hydrochloride; KOH: potassium hydroxide; M: mycological cure rate; MR: mycological recurrence rate; N: no clinical improvement rate; S: stigma; N/a: not applicable; NC: negative culture; O: decrease in onychomycosis severity index score; OP: overall problem; OSI: onychomycosis severity index score; PA: physical activities problems; PS: patient satisfaction; R: recurrence rate; RL: relapse rate; S: stigma; SB: symptom bothersomeness; SCIO: Scoring Clinical Index for Onychomycosis; SF: symptom frequency; TS: treatment satisfaction. * Significant difference between treatment groups. † Studies showing significant benefit of combination therapy over monotherapy.
Of the 15 medication-only studies (Table 1), the average number of subjects was 139.1 [standard deviation (SD): 135.5; range: 10–595], with average treatment duration of 31.0 weeks (SD: 21.4; range 4–65). Terbinafine (8/15, 53.3%) and amorolfine (6/15, 40.0%) were the most commonly studied oral and topical medications, respectively. Most studies (11/15, 73.3%) investigated an oral medication in combination with a topical medication, with oral terbinafine and topical amorolfine (4/11, 36.4%), and oral terbinafine and topical ciclopirox (3/11, 27.3%) being most common, with more than half (7/11, 63.6%) designed with the topical medication administered for longer than the oral medication. Common endpoints assessed were mycological cure rates in 13 (86.7%), complete cure rates in 10 (66.7%), and clinical cure rates in 6 (40.0%) studies, with 5 studies (33.3%) reporting all 3 cure rates.

Significant clinical benefit of medication combination therapy vs. monotherapy was observed in 60% (9/15) of studies (Table 1). Studies investigating oral terbinafine and topical amorolfine reported significantly greater mycological cure rates at 3 months (94.2% vs. 59.7%; \( p < 0.001 \)) [22], and complete [72.3% vs. 37.5%; 95% confidence interval (CI): 57.4–84.4 vs. 23.9–52.6] [20], (59.2% vs. 45.0%; \( p = 0.03 \)) [22], and clinical cure rates (74% vs. 42%; 95% CI: 60–86 vs. 28–57) [21] at 18 months in the combination vs. oral terbinafine monotherapy groups. Studies examining oral griseofulvin combined with topical tioconazole or bifonazole showed significantly higher complete cure rates at 12 months (69% vs. 41%; \( p < 0.005 \)) [18], and significantly higher mycological cure rates (93% vs. 66%, \( p < 0.01 \)) and lower relapse rates (7% vs. 20%, \( p < 0.01 \)) at 4 months [19] compared to oral griseofulvin monotherapy treatment. Combination of topical therapies only (bifonazole and urea) resulted in significantly greater complete (50.7% vs. 40.9%; \( p = 0.0260 \)) and mycological (61.5% vs. 49.1%, \( p = 0.0033 \)) cure rates at 3 months compared to urea monotherapy, but this result was not sustained at 6 months [26]. Combinations of topical fluconazole and urea showed higher mycological cure (82.8% vs. 62.6%) and clinical improvement (71.1% vs. 68.0%) rates than fluconazole alone at 6 months, however \( p \)-values were not reported [27].

Conflicting results were found in studies combining oral itraconazole and topical amorolfine vs. itraconazole monotherapy, with one study reporting significantly greater mycological (\( \geq 90\% \) vs. \( < 69\% \); \( p < 0.001 \)) and complete cure rates (83.7–93.9% vs. 68.8%; \( p = 0.011 \)) at 24 weeks [28], and another reporting no significant differences at 3 months [29]. One study on oral terbinafine and topical ciclopirox combination therapy vs. oral terbinafine monotherapy found significantly greater mycological cure rates (88.2% vs. 64.7%; \( p = 0.043 \)) and markedly improved or cured target toenail (82.4% vs. 58.8%; \( p = 0.0044 \)) at 9 months [21], while others reported no significant differences at 48 weeks [24] or 9 months [25]. One study investigating oral therapies only (itraconazole and terbinafine) found significantly higher mycological (66.7% vs. 46.3%; \( p = 0.007 \)), complete (48.1% vs. 30.5%; \( p = 0.03 \)), and effective therapy (60.5% vs. 43.2%; \( p = 0.02 \)) rates at 72 weeks vs. oral terbinafine monotherapy [30], while another found no significant differences in recurrence rates at 48 weeks [31]. Combinations of oral itraconazole or griseofulvin and topical isoconazole or urea showed no clinical benefit of combination therapy over monotherapy [32].

In seven medication-based studies that reported adverse events, 57.1% reported greater adverse events in monotherapy groups compared to combination groups. Cost (treatment cost per cured patient or cost per cure ratio) for oral terbinafine and topical amorolfine vs. oral terbinafine [22] and oral itraconazole and topical amorolfine vs. oral itraconazole [28,29] was lower for combination therapy than monotherapy.

Of the 15 studies investigating medications combined with procedures (Table 2), the average number of subjects was 114.2 (SD: 160.82; range: 9–504) with an average treatment duration of 21.4 weeks (SD: 13.4; range: 3–52). The majority of studies (10/15, 66.7%) utilized laser therapy, with laser and topical therapy (7/10, 70%) more common than oral therapy (3/10, 30%), and 1064-nm Nd:YAG being the most commonly used laser (6/10, 60%). The most common combination overall was laser and topical amorolfine (3/15, 20%), and the most common medications were oral terbinafine (4/15, 26.7%) and topical amorolfine (3/15, 20%). Common endpoints assessed were mycological cure rates in 11
(73.3%), clinical cure rates in seven (46.7%), and complete cure rates in two (13.3%) studies, with only one study (6.7%) reporting all three cure rates.

Significant clinical benefit of procedural and medication combination therapy vs. monotherapy was observed in almost all (14/15, 93.3%) studies (Table 2). Studies investigating laser therapy and topical amorolfine reported significantly greater mycological cure rates at 24 weeks (75 vs. 20; \( p = 0.001 \)) [33] and 3 months (65% vs. 35%; \( p = 0.05 \)) [34] in the combination vs. topical amorolfine and laser monotherapy groups, respectively. Similar improvements in mycological cure rates at 24 weeks (66.67–100% vs. 35.29–61.54%, \( p < 0.05 \)), as well as decreases in onychomycosis severity index (OSI) scores (2–8 vs. 1–4; \( p < 0.002 \)) were reported in another study [35]; however, significant differences were only observed in patients with mild and moderate onychomycosis, with no significant improvements in patients with severe onychomycosis treated with combination therapy for either metric (\( p > 0.05 \), both). Laser and topical efinaconazole combination resulted in significantly greater improvement in the Scoring Clinical Index for Onychomycosis (SCIO) index at 36, 48 (both \( p = 0.04 \)), and 52 weeks (\( p = 0.02 \)) compared to topical efinaconazole monotherapy, with no significant difference in mycological cure rates [36]. Laser and topical tioconazole had significantly higher clinical cure, patient satisfaction, negative potassium hydroxide, and negative fungal culture (55%, 60%, 80%, 70%, respectively) rates than laser (30%, 40%, 55%, 30%, respectively) or topical tioconazole (25%, 30%, 55%, 30%, respectively) monotherapies (\( p < 0.05 \), all) [39]. Laser and topical luliconazole resulted in significantly greater mycological cure rates 3 months after the last treatment (69.6% vs. 57.4%; \( p = 0.006 \)) and clinical cure rates at 3 (69.6% vs. 50.9%; \( p = 0.004 \)) and 6 months (73.0% vs. 52.8%; \( p = 0.002 \)) than laser monotherapy [40]. Laser and topical naftifine hydrochloride spray showed significant improvements in mycological (22.5% vs. 4.5%) and clinical cure (40.8% vs. 7.5%) at 24 weeks, however laser monotherapy also showed significant benefit over topical monotherapy for both clinical and mycological cure rates (\( p < 0.005 \), all) [42].

In studies assessing laser and oral itraconazole combination therapy, efficacy rate (cure (new clear nail growth with less than 5% nail dystrophy) plus significant efficacy (60% new clear nail growth) rates) were significantly higher at 8 (20% vs. 13%) and 24 weeks (21% vs. 11%) (\( p < 0.05 \), both) compared to laser monotherapy, only for patients with severe onychomycosis, with no significant differences across groups in patients with mild/moderate onychomycosis (\( p > 0.05 \)) [37]. In another study, overall clinical cure rate was significantly greater (\( p = 0.001 \)) and mean OSI score after treatment significantly lower (\( p < 0.01 \)) in laser and oral itraconazole combination group vs. oral itraconazole monotherapy, however mycological responses did not significantly differ [38]. Laser and oral terbinafine combination therapy resulted in significantly greater mycological and clinical cure rates at 4, 8, 12, 16, and 24 weeks vs. both laser and terbinafine monotherapies (\( p < 0.05 \), all) [41].

Studies examining debridement and oral terbinafine vs. terbinafine monotherapy reported significant improvements in symptom frequency (\( p = 0.0395 \)) and treatment satisfaction (\( p = 0.0077 \)) based on a validated onychomycosis-specific patient-reported outcomes questionnaire [45], and significantly greater clinical cure rates (59.8% vs. 51.4%; \( p = 0.023 \)) [44], however there were no differences in mycological or complete cure rates (\( p > 0.05 \)). Debridement with topical ciclopirox resulted in significantly greater mycological cure rates than debridement alone (76.74% vs. 0%; \( p < 0.05 \)) [46]. Combination of nail drilling plus oral and topical terbinafine resulted in significantly greater mean percent clear nail at 16 (63.75% vs. 31.36%; \( p = 0.028 \)) and 22 weeks (59.38% vs. 23.81%; \( p = 0.005 \)) vs. topical terbinafine monotherapy, while nail drilling and topical terbinafine combination therapy resulted in significant improvement in mean percent clear nail at 22 weeks only (52.39% vs. 23.81%; \( p = 0.014 \)) [47]. Mycological cure rates did not differ significantly amongst any groups. Methyl aminolevulinate photodynamic therapy and topical urea combination therapy showed no significant differences in mycological (\( p = 0.178 \)) or complete (\( p = 0.23 \)) cure rates vs. urea monotherapy [43].
Adverse events were reported in seven studies, with almost half (3/7, 42.9%) not differentiating between procedural/medication and control treatment groups. Three studies (75%) reported greater adverse events in combination vs. monotherapy groups. Information on cost was not provided in any study.

4. Discussion/Conclusions

Our study showed that medication-only combination therapy showed efficacy compared to monotherapy for onychomycosis treatment in more than half of trials, with limited adverse events. However, seven studies had conflicting results and in studies that showed greater efficacy for monotherapy vs. combination therapy, significance was not sustained at later endpoints [26] or was only observed in the groups with longer treatment durations (i.e., oral terbinafine 12 vs. 6 weeks) [20,21]. Importantly, trial lengths were relatively short, with average follow-up of 46.1 weeks (SD: 21.5; range: 24–78.2 weeks). In contrast, pivotal RCTs on oral terbinafine [8,48–63], oral itraconazole [8,50,52–54,56,58–60,63–67], and topical efinaconazole [68–71] had average follow-ups of 69.0 (SD: 49.1; range: 36–252), 66.4 (SD: 55.8; range: 19–252), and 62.1 (SD: 28.7; range: 40–104.3) weeks, respectively. Taken together, medicine-only combination therapy trials were much less rigorously designed than pivotal monotherapy trials, and therefore should be interpreted with caution.

We found that seven medication-based studies yielded conflicting results, with similar quality across studies. Two studies showed conflicting results for oral itraconazole and topical amorolfine therapy, with one study including 131 patients, multicenter, and 5.5 months of follow-up [28], versus 90 patients, single-center, and 9 months of follow-up [29]. Three studies showed conflicting results for oral terbinafine and topical ciclopirox combination therapy, with one study including 80 patients, single-center, 9 months of follow-up, and non-blinded [23], another including 73 patients, multi-center, 11 months of follow-up, and single-blinded [24], and a final study including 96 patients, single-center, 8.3 months of follow-up, and single-blinded [25]. Two studies had conflicting results on oral itraconazole and oral terbinafine combination therapy, with one study including 190 patients, multicenter, 16.6 months of follow-up, and single-blinded [30], versus 106 patients, multicenter, and single-blinded [31]. Given that these trials with conflicting results were comparable in terms of quality, without a clearly superior trial demonstrating greater efficacy for combination vs. monotherapy treatments, large, multicenter, double-blinded trials with sufficient follow-up are necessary to determine the efficacy of combination therapy for onychomycosis treatment.

In three medication-only studies that provided cost information, combination therapy was more cost effective than monotherapy, considering duration of usage and efficacy. However, this data cannot be extrapolated to include combination oral therapy with the newer topicals. In a review of data from the National Average Drug Acquisition Cost Medicaid Pharmacy Pricing database, 2013–2018 [72], inflation-adjusted costs changed at an annual rate of −18.2% and −3.4% for generic oral itraconazole and terbinafine, respectively, while brand name medications Kerydin, Jublia, and Diflucan increased 3.7%, 4.5%, and 17.2%, respectively. This data suggests that branded topical and oral antifungals are costly, and that prescribing them as part of combination regimens will increase health care costs. In a study evaluating the cost of topical efinaconazole 10% solution [73], a 48-week treatment course for one great toenail ($8057) was nearly 35 and 12 times more expensive than projected costs (using data from goodrx.com, accessed on 1 July 2021) of 3 months of treatment with oral terbinafine (250 mg/day, $233) and oral itraconazole (200 mg/day, $683), respectively, without consideration of relative efficacy. In an analysis of Medicare provider utilization and payment data, part D, 2013–2018 [74], total costs and costs per supply day increased yearly by 3091% and 144%, respectively, for topical efinaconazole, and decreased and increased by 12.5% and 42.4%, respectively, for topical tavaborole. Therefore, more research is necessary to assess cost vs. benefits of combination treatments compared to monotherapy.
We found that almost all studies examining combination procedural and medication therapy showed significant benefit compared to monotherapy. However, trials were relatively short, with an average follow-up of 32.5 weeks (SD: 14.3; range: 13.04–62.0 weeks). RCTs on photodynamic and laser monotherapies had a similar average follow-up of 35.3 weeks (SD: 11.5; range: 24.0–52.0 weeks) [75–85], which suggests that procedural studies, in general, lack the long-term follow-up that is sufficient to determine efficacy of onychomycosis treatment. Furthermore, in our review, some monotherapy and combination arms did not demonstrate efficacy for severe onychomycosis cases [35]. In a review of 24 laser trials on onychomycosis [86], there was limited evidence supporting lasers for onychomycosis cure, and only 30% and 20% of RCTs described methods of randomization or utilized blinding in their experimental design, respectively. Furthermore, in a systematic review of 25 RCTs investigating laser monotherapy for toenail onychomycosis [87], mycological cure was evaluated in only one study, and complete cure was not reported in any study. Mean OSI changes from baseline were minimal (range: −3.6 to +1.4), and efficacies of control and treatment groups were similar, thereby failing to demonstrate improvements in the US FDA approved endpoint “temporary increase of clear nail” [3]. Methodology of current laser trials is inadequate, both for monotherapy trials and for combination trials reported in this review. Therefore, laser monotherapy efficacy should be confirmed in rigorous RCTs, before it can be considered for use in conjunction with other onychomycosis medications.

While cost was not reported in any procedural and medication combination trials evaluated in this review, laser treatments are expensive, not covered by insurance, and typically require multiple monthly sessions [3]. Considering that laser therapies are less efficacious than topical or oral therapeutic options [6] and are costly, we caution against use of lasers in combination with antifungals until more robust RCTs are conducted, demonstrating superior efficacy with favorable cost–benefit profiles.

We found that combination therapy was generally well tolerated across medication-only studies. Notably, in a systematic review and meta-analysis of 26 RCTs investigating monotherapy for toenail onychomycosis [5], the OR of adverse events in any treatment group did not significantly differ from placebo, except in the case of efinaconazole 10% solution (OR 1.28; 95% CI: 1.02–1.61), for transient application-site reactions. Therefore, since monotherapy for onychomycosis treatment is well tolerated, we recommend single medication therapy to limit adverse effects. In procedural and medication studies, we found greater reports of adverse events with combination therapy than monotherapy, however, sample sizes were small, and in all three studies, monotherapy was a topical or placebo treatment, rather than a procedural treatment. It is therefore uncertain whether the adverse event in the combination group was due to the procedure itself (i.e., skin irritation from laser treatment), or due to the combination of treatments. In a systematic review of 35 RCTs (1723 patients and 4278 nails with onychomycosis) [88], the majority of patients reported a mild-to-moderate burning sensation during laser treatment, with some reporting bleeding.

In pivotal RCTs investigating oral terbinafine monotherapy, adverse effects were transient, mild to moderate in severity, and not significantly different from placebo groups [89]. There were no reported laboratory abnormalities [90]. In the terbinafine package insert, liver enzyme abnormalities and taste disturbances were only reported in 3.3% and 2.8% of patients, respectively, with a discontinuation rate of 0.2% for both [https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf, accessed on 18 January 2022]. Oral itraconazole monotherapy is well tolerated, with the most common reported adverse events being gastrointestinal discomfort and headache, both mild and transient [66], and with safety profiles similar between placebo and itraconazole treatment groups in a phase-III RCT [64]. In two phase-III multicenter RCTs assessing topical efinaconazole monotherapy [68], rates of adverse events were similar between treatment and vehicle groups in both studies, with most mild or moderate in severity, low rates of treatment-related discontinuation, and no clinically meaningful laboratory or vital sign changes from baseline. Therefore, when used as monotherapy, FDA-approved onychomycosis treatments
have limited side effects, with none that are life threatening, and rarely lead to medication discontinuation. However, it is important to note that oral itraconazole and fluconazole are contraindicated with certain medications. In addition, oral itraconazole, fluconazole, and terbinafine, can alter the plasma concentration of select medications [6]. Considering the frequency of drug interactions of oral onychomycosis therapies with other medications, initiation of oral combination therapy would therefore require close monitoring of patients on multiple medications, with medication adjustments or dose reductions more likely than for patients on monotherapy treatment.

In a meta-analysis of 26 RCTs investigating systemic monotherapy for toenail onychomycosis [5], there was significantly greater OR of achieving mycological cure for all treatments vs. placebo, with continuous itraconazole 200 mg (OR: 18.61; 95% CI: 7.40–46.81) and continuous terbinafine 250 mg (OR: 16.41; 95% CI: 6.49–41.47) the most efficacious treatments. Monotherapy therefore is effective in treating onychomycosis. Therefore, taken together with our analysis of combination therapy for onychomycosis, monotherapy should be considered as a first-line treatment option prior to initiating combination therapy.

Poor prognostic factors for onychomycosis treatment include patient characteristics (older age, history of personal history of onychomycosis), comorbidities (immunosuppression, peripheral vascular disease, uncontrolled diabetes mellitus), nail characteristics (prior nail trauma, proximal subungual onychomycosis, dermatophytoma, severe onycholysis), and infecting organism (mixed fungal infection, yeasts, non-dermatophytes) [6]. Predisposition to mucocutaneous fungal infections may be due to specific genotypes. For example, Tyr238X dectin-1 or caspase recruitment domain containing protein-9 mutations cause impaired β-glucan recognition and cytokine responses, and defects in major histocompatibility complexes may interfere with initial fungi recognition and prevent T-cell activation. Alterations in intercellular adhesion molecule-1 may prevent immune cells from migrating to infected tissues, and elevated levels of T-regulatory cells may modify T-cell behavior, all of which may increase susceptibility to dermatophyte and Candida spp. infections [91,92].

In patients with poor prognostic factors, the advantages of combination therapy may outweigh the risks and costs, and should be considered especially in patients who failed previous treatments. Importantly, we found that in many combination trials, patients with poor prognostic factors or risk factors for recurrence were excluded. In medication-only studies, six provided no information on exclusion criteria, while 66.7% (6/9) of studies with exclusion criteria included a risk factor for poor prognosis or high risk of recurrence. There was an upper age limit for inclusion in the study in 20% (3/15) of studies. In procedural and medication studies, all studies included information on exclusion criteria, with 66.7% (10/15) including a risk factor for poor prognosis or high risk of recurrence. Upper age limits for inclusion were reported in 26.7% (4/15) of studies. Medication-based monotherapy trials showed good efficacy in some subgroups, including older adults [52], diabetics [75,93–95], and those with severe onychomycosis [66] or dermatophytoma [96]. Therefore, published combination trials excluded many patients who may have benefited most from combination therapy, such as older patients and the immunocompromised, and future trials must be conducted in these patient populations to determine the efficacy of combination therapy in difficult-to-treat onychomycosis cases.

Considering the limited number of studies available for review, conflicting results in medication-only based studies, limited efficacy of procedural combination treatments, and cost considerations, we recommend that combination therapy be considered as a second-line treatment option for patients with resistant cases of onychomycosis or poor prognostic features. Our data showed that combinations of oral griseofulvin and topical tioconazole or bifonazole, or oral terbinafine and topical amorolfine, demonstrated significant improvements in combination vs. monotherapy group in all trials. Oral terbinafine, itraconazole, and griseofulvin are US FDA approved for onychomycosis treatment, however, griseofulvin is no longer commonly used, considering its inferior efficacy compared to other treatment options, lengthier treatment courses, and higher risk of adverse effects [3].
Topical efinaconazole 10% and tavaborole 5% solution are US FDA approved for toenail onychomycosis, with ciclopirox 8% nail lacquer approved for both fingernail and toenail onychomycosis [6], and topical tioconazole, bifonazole, and amorolfine are not currently available in the US. A panel of expert dermatologists, podiatrists, and a microbiologist [4], recommended that terbinafine and efinaconazole 10% solution should be used as first-line oral and topical onychomycosis treatments, respectively. Considering these recommendations, the results from our study, and accessibility of antifungal treatments in the US, we recommend oral terbinafine as first line, used alone for straightforward moderate to severe onychomycosis cases, and in combination with efinaconazole 10% solution, tavaborole 5% solution, or ciclopirox 8% nail lacquer for patients who failed previous treatments or who have poor prognostic factors. Nonetheless, medication selection must be tailored to each individual patient with consideration of the extent of nail involvement, infecting pathogen, comorbidities, concomitant medications, expense, and patient preferences [6].

Retinoids in combination with antifungals may be effective for onychomycosis treatment. Retinoids have both in vitro and in vivo antimicrobial activity against fungi, with tretinoin and isotretinoin most effective against *M. furfur*, tazarotene against dermatophytes, and tretinoin against *A. fumigatus* and *C. albicans*. By preventing hyphal germination necessary for biofilm formation, all-trans retinoic acid may also be effective against *Candida* biofilm-related infections, which are typically difficult to treat due to multidrug resistance [97]. In a study performed after our systematic search on 135 patients with toenail and/or fingernail onychomycosis receiving oral itraconazole pulse monotherapy, oral acitretin monotherapy, or combined pulsed itraconazole and acitretin for 3 months [98], mycological cure was 51.1%, 28.9%, and 80%, respectively, and complete cure was 20%, 28.9%, and 53.3%, respectively ($p \leq 0.05$). OSI scores significantly improved in the combination group compared to itraconazole monotherapy ($p = 0.005$) and acitretin monotherapy ($p = 0.006$) groups, with no difference observed between the monotherapy groups ($p = 0.95$). Therefore, retinoids combined with antifungals may increase efficacy compared to monotherapy treatments. Large RCTs are needed to corroborate these findings.

There are several limitations to our study. While we performed an exhaustive search of combination studies for onychomycosis treatment, only a small number met inclusion criteria for our review. Different endpoints and medication combinations were used across studies, limiting the ability to make direct comparisons of study findings. It is also difficult to draw comparisons about studies that use keratolytic agents in combination with topical antifungals. Furthermore, study inclusion/exclusion criteria differed across studies (Table 3). Nail characteristics variably specified fingernail vs. toenail, number of affected nails, matrix involvement, and nail plate surface area and thickness. *T. rubrum* was the etiological agent in most studies, while others did not list the fungal organisms, or reported mixed infections. Vehicles differed, including nail lacquers, creams, and solutions, likely contributing to differences in efficacy. The majority of studies were conducted in Europe or North America, limiting the diversity of participants.

Future research should be directed at conducting combination clinical trials that are large, multicenter, and randomized, with sufficient follow-up, and including diverse patient populations across different geographic locations, to determine the value of combination therapy for treatment of onychomycosis, and to establish standard treatment regimens. Until such studies are conducted, and a clear clinical benefit of combination therapy is demonstrated, we recommend combination therapy as a second-line option in patients with difficult-to-treat cases or poor prognostic factors.
Table 3. Nail characteristics, pathogens, topical vehicles, and study location for all 30 studies.

| Study | Combination Therapy | Pathogen(s) | Fingernail or Toenail Involvement | Number of Affected Nail(s) for Inclusion | Nail Characteristics for Inclusion | Topical Vehicles | Study Location |
|-------|---------------------|-------------|-----------------------------------|----------------------------------------|-----------------------------------|-----------------|---------------|
| Hay, R. J. et al., 1987 [18] | Oral griseofulvin & topical tioconazole | *T. rubrum* (100%) | Bilateral toenails | N/A | N/A | Nail solution | United Kingdom |
| Friedman-Birnbaum, R. et al., 1997 [19] | Oral griseofulvin & topical bifonazole | *T. rubrum* (93%), *T. tonsurans* (4%), *T. mentagrophytes* (3%) | 93% toenail, 7% fingernail | N/A | N/A | Cream | Israel |
| Baran, R. et al., 2000 [20] | Oral terbinafine & topical amorolfine | *T. rubrum* (98%), *T. interdigitale* (1.4%), *T. soudanense* (0.7%) | Toenails | N/A | Matrix involvement | Nail lacquer | France |
| Baran, R. 2001 [21] | Oral terbinafine & topical amorolfine | *T. rubrum* (98%), *T. interdigitale* (1.4%), *T. soudanense* (0.7%) | Toenails | At least 1 (not including little toenail) | ≥80% of the nail plate surface area and/or matrix involvement | Nail lacquer | France |
| Baran, R. et al., 2007 [22] | Oral terbinafine & topical amorolfine | *T. rubrum* (93.3%), *T. mentagrophytes* (4.4%), *S. brevicatilis* (0.8%), *T. interdigitale* & *Acremonium* spp. (both 0.4%) | Toenails | At least 1 great toenail | Matrix involvement | Nail lacquer | Europe |
| Avner, S. et al., 2005 [23] | Oral terbinafine & topical ciclopirox | *T. rubrum* (95.6%), *T. mentagrophytes* (4.4%) | Toenails and/or fingernails | N/A | No lunula involvement | Nail lacquer | Israel |
| Gupta, A. K. et al., 2005 [24] | Oral terbinafine & topical ciclopirox | Dermatophytes (not specified further) | Toenails | At least 1 great toenail | ≥60% of the nail plate surface area and/or lunula/matrix involvement | Nail lacquer | Canada & US |
| Jaiswal, A. et al., 2007 [25] | Oral terbinafine & topical ciclopirox or amorolfine | *T. rubrum* (60%), *T. mentagrophytes* (13.3%), *T. tonsurans* (8.4%), *C. albicans* (15.6%), *Aspergillus* spp. (6.7%), *Scopulariopsis* spp. (2.2%) | Toenails and/or fingernails | N/A | N/A | Nail lacquer | India |
| Study | Combination Therapy | Pathogen(s) | Fingernail or Toenail Involvement | Number of Affected Nail(s) for Inclusion | Nail Characteristics for Inclusion | Topical Vehicles | Study Location |
|-------|---------------------|-------------|-----------------------------------|------------------------------------------|-----------------------------------|-----------------|---------------|
| Tietz, H. J. et al., 2013 [26] | Topical bifonazole & urea | *T. rubrum* (92–93%), *T. interdigitale* (5–6%), other (5–7%) | Toenails and/or fingernails | At least 1 but not more than 3 nails | Affected nail plate surface area 20–50% of target nail | Cream, paste | Germany |
| Bassiri-Jahromi et al., 2012 [27] | Topical fluconazole & urea | *T. rubrum* (78.8%), *T. mentagrophytes* (19.7%), *T. verrucosum* (1.5%) | Toenails and/or fingernails | N/A | At least 25% nail plate surface area of target nail and at least 2 mm of healthy nail from the nail fold to the proximal nail plate | Nail lacquer | Iran |
| Lecha, M. 2001 [28] | Oral itraconazole & topical amorolfine | *T. rubrum* (64.9%), *Candida* spp. (16.7%), *S. brevicaulis* (10.5%), *T. mentagrophytes* (8.8%), other (4.4%) | Toenails | At least 1 (not including little toenail) | Matrix area involvement and/or ≥80% total nail surface involvement | Nail lacquer | Spain |
| Rigopoulos, D. et al., 2003 [29] | Oral itraconazole & topical amorolfine | *C. albicans* (94.4%), *C. parapsilosis* (3.3%), other *Candida* spp. (2.2%) | Fingernails | N/A | At least 50% of the whole nail surface | Nail lacquer | Greece |
| Gupta, A. K. et al., 2001 [30] | Oral itraconazole & terbinafine | *T. rubrum* (92.1%), *T. mentagrophytes* (7.9%) | Toenails | N/A | N/A | N/A | Canada & US |
| Gupta, A. K. et al., 2013 [31] | Oral itraconazole & terbinafine | *T. rubrum* (86.7%), *T. mentagrophytes* (13.3%) | Toenails | At least 1 great toenail | 20–100% affected nail plate surface area | N/A | Canada |
| Arenas, et al., 1991 [32] | Oral itraconazole or griseofulvin & topical isoconazole or urea | *T. rubrum* (37.7%), unknown (28.6%), mixed (16.6%), *Candida* spp. (16%), *T. mentagrophytes* (1.1%) | Toenails | At least 1 great toenail | N/A | Cream | Mexico |
| Zhang, J. et al., 2016 [33] | Laser & topical amorolfine | *T. rubrum* (88.9%), *C. albicans* (11.1%) | Bilateral fingernails and/or bilateral toenails | N/A | N/A | Nail lacquer | China |
| Bunyaratavej, S. et al., 2020 [34] | Laser & topical amorolfine | *N. dimidiatum* (75%), *Fusarium* spp. (25%) | Toenails | N/A | No involvement of nail matrix | Nail lacquer | Thailand |
| Study                        | Combination Therapy                  | Pathogen(s)                                                                 | Fingernail or Toenail Involvement | Number of Affected Nail(s) for Inclusion | Nail Characteristics for Inclusion | Topical Vehicles  | Study Location |
|-----------------------------|-------------------------------------|----------------------------------------------------------------------------|------------------------------------|------------------------------------------|-----------------------------------|--------------------|-----------------|
| Zhang, J. et al., 2021 [35] | Laser & topical amorolfine          | *T. rubrum* (67.9%), *Candida* spp. (19.2%), *T. mentagrophytes* (3.8%), *A. fumigatus* (1.3%) | Toenails                           | At least 1 great toenail                 | N/A                               | Nail lacquer      | China           |
| Bonhert, K. et al., 2019 [36]| Laser & topical efinaconazole       | Dermatophyte or mixed dermatophyte/*Candida* spp.                          | Toenails                           | At least 1 great toenail                 | Uninfected length 3 mm or more (from the proximal nailfold) and 3 mm or less in thickness | Nail solution      | US              |
| Li, Y. et al., 2016 [37]    | Laser & oral itraconazole           | Not reported                                                                | Toenails and/or fingernails        | N/A                                      | N/A                               | N/A                | China           |
| Hamed Khater, M. & Khattab, F.M. 2020 [38] | Laser & oral itraconazole | Yeast (31%), non-dermatophytes molds (28.5%), dermatophyte (22%), *Trichosporon* spp. (18.5%) | Toenails and/or fingernails        | N/A                                      | N/A                               | N/A                | Egypt           |
| Zaki, A.M. et al., 2020 [39] | Laser & topical tioconazole         | *Trichosporon* spp.                                                       | Toenails and/or fingernails        | N/A                                      | N/A                               | Nail solution      | Egypt           |
| Zhou, B.R. et al., 2016 [40]| Laser & topical luliconazole        | *T. rubrum* (74.8%), *T. mentagrophytes* (16.1%), *C. albicans* (9%)        | Toenails and/or fingernails        | N/A                                      | N/A                               | Cream              | China           |
| Xu, Y. et al., 2014 [41]    | Laser & oral terbinafine            | Not reported                                                                | Toenails and/or fingernails        | N/A                                      | N/A                               | N/A                | China           |
| Kim, T.I. et al., 2016 [42] | Laser & topical naftifine HCl spray| *T. rubrum* (73.2%), *Candida* spp. (16.1%), *T. mentagrophytes* (10.7%)   | Toenails and/or fingernails        | N/A                                      | N/A                               | Spray              | Korea           |
| Gilaberte, Y. et al., 2017 [43]| Methyl aminolevulinate photodynamic therapy & topical urea | *T. rubrum* (30%), *Aspergillus* spp. (15%), *T. mentagrophytes*, *Fusarium* spp. & other (all 7.5%), *S. brevicaulis* (5%) | Toenails and/or fingernails        | N/A                                      | N/A                               | Ointment           | Spain           |
Table 3. Cont.

| Study                          | Combination Therapy                  | Pathogen(s)                                                                 | Fingernail or Toenail Involvement | Number of Affected Nail(s) for Inclusion | Nail Characteristics for Inclusion | Topical Vehicles | Study Location |
|--------------------------------|--------------------------------------|-------------------------------------------------------------------------------|-----------------------------------|------------------------------------------|-----------------------------------|------------------|----------------|
| Jennings, M.B. et al., 2006 [44] | Debridement & oral terbinafine       | Dermatophytes (not specified further)                                       | Toenails                         | At least 1 great toenail                | N/A                                          | N/A              | US             |
| Potter, L.P. et al., 2007 [45]   | Debridement & oral terbinafine       | Not reported                                                                  | Toenails                         | At least 1 great toenail                | N/A                                          | N/A              | US             |
| Malay, D.S. et al., 2009 [46]    | Debridement & topical ciclopirox     | Candida spp. (28%), *T. rubrum* & mixed (both 23.2%), *Aspergillus* spp. & other saprophyte (both 10.4%), *T. mentagrophytes* (4.8%) | Toenails                         | N/A                                      | N/A                                          | Nail lacquer     | US             |
| Shemer, A. et al., 2016 [47]     | Nail drilling, oral & topical terbinafine | *T. rubrum* (88.8%), *T. mentagrophytes* (11.2%)                          | Toenails                         | N/A                                      | ≤75% nail involvement with no lunula involvement | Spray            | Israel         |

N/A: not applicable; US: United States.
Author Contributions: Both J.M.F. and R.L. contributed equally to the work. Study concept and design: S.R.L.; acquisition of data: J.M.F., R.L. and S.R.L.; analysis and interpretation of data: J.M.F., R.L. and S.R.L.; drafting of the manuscript: J.M.F. and R.L.; critical revision of the manuscript for important intellectual content: S.R.L.; study supervision: S.R.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

Conflicts of Interest: Authors Falotico and Lapides have no conflict of interest. Author Lipner has served as a consultant for Ortho Dermatologics, Verrica, and Hoth Therapeutics, BelleTorus Corporation, and Hexima.

References

1. Lipner, S.R.; Scher, R.K. Onychomycosis: Clinical overview and diagnosis. J. Am. Acad. Dermatol. 2019, 80, 835–851. [CrossRef] [PubMed]
2. Aggarwal, R.; Tarqhotra, M.; Kumar, B.; Sahoo, P.; Chauhan, M. Treatment and management strategies of onychomycosis. J. Mycol. Med. 2020, 30, 100949. [CrossRef] [PubMed]
3. Ricardo, J.W.; Lipner, S.R. Safety of current therapies for onychomycosis. Expert Opin. Drug Saf. 2020, 19, 1395–1408. [CrossRef] [PubMed]
4. Lipner, S.R.; Joseph, W.S.; Vlahovic, T.C.; Scher, R.K.; Rich, P.; Ghannoum, M.; Daniel, C.R.; Elewski, B. Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US. J. Drugs Dermatol. JDD 2021, 20, 1076–1084. [CrossRef] [PubMed]
5. Gupta, A.K.; Foley, K.A.; Mays, R.R.; Shear, N.H.; Piguet, V. Monotherapy for toenail onychomycosis: A systematic review and network meta-analysis. Br. J. Dermatol. 2020, 182, 287–299. [CrossRef] [PubMed]
6. Lipner, S.R.; Scher, R.K. Onychomycosis: Treatment and prevention of recurrence. J. Am. Acad. Dermatol. 2019, 80, 853–867. [CrossRef] [PubMed]
7. Baran, R.; Kaoukhov, A. Topical antifungal drugs for the treatment of onychomycosis: An overview of current strategies for monotherapy and combination therapy. J. Eur. Acad. Dermatol. Venereol. 2005, 19, 21–29. [CrossRef]
8. Sigurgeirsson, B.; Ólafsson, J.H.; þ Steinsson, J.; Paul, C.; Billstein, S.; Evans EG, V. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: A 5-year blinded prospective follow-up study. Arch. Dermatol. 2002, 138, 353–357. [CrossRef]
9. Gupta, A.K.; Sibbald, R.G.; Andriessen, A.; Belley, R.; Boroditsky, A.; Botros, M.; Chelin, R.; Gulliver, W.; Keast, D.; Raman, M. Toenail onychomycosis—A Canadian approach with a new transungal treatment: Development of a clinical pathway. J. Cutan. Med. Surg. 2015, 19, 440–449. [CrossRef]
10. Markinson, B.C.; Vlahovic, T.C.; Joseph, W.S.; Scher, R.K.; Tosti, A.; Plasencia, J.; Pariser, D.M. Diagnosis and management of onychomycosis: Perspectives from a joint podiatry-dermatology roundtable. J. Am. Podiatr. Med. Assoc. 2016, 106, 155–162. [CrossRef]
11. Olafsson, J.; Sigurgeirsson, B.; Baran, R. Combination therapy for onychomycosis. Br. J. Dermatol. 2003, 149, 15–18. [CrossRef] [PubMed]
12. Polak, A. The past, present and future of antifungal combination therapy. Mycoses 1999, 42, 355–370. [CrossRef] [PubMed]
13. Evans, E. The rationale for combination therapy. Br. J. Dermatol. 2001, 145, 9–13. [CrossRef]
14. Bristow, I.R.; Baran, R. Topical and oral combination therapy for toenail onychomycosis: An updated review. J. Am. Podiatr. Med. Assoc. 2006, 96, 116–119. [CrossRef] [PubMed]
15. Hay, R. The future of onychomycosis therapy may involve a combination of approaches. Br. J. Dermatol. 2001, 145, 3–8. [CrossRef]
16. Gupta, A.K.; Ryder, J.E.; Baran, R. The use of topical therapies to treat onychomycosis. Dermatol. Clin. 2003, 21, 481–489. [CrossRef]
17. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [CrossRef]
18. Hay, R.; Clayton, Y.; Moore, M. A comparison of terbinafine 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin. Exp. Dermatol. 1987, 12, 175–177. [CrossRef]
19. Friedman-Birnbaum, R.; Cohen, A.; Shenker, A.; Bitterman, O.; Bergman, R.; Stettendorf, S. Treatment of onychomycosis: A randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Int. J. Dermatol. 1997, 36, 67–69. [CrossRef]
20. Baran, R.; Feuilhade, M.; Datry, A.; Goettmann, S.; Pietrini, P.; Viguie, C.; Badillet, G.; Larnier, C.; Czernielewski, J. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. *Br. J. Dermatol.* 2000, 142, 1177–1183. [CrossRef]

21. Baran, R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. *Br. J. Dermatol.* 2001, 145, 15–19. [CrossRef] [PubMed]

22. Baran, R.; Sigurgeirsson, B.; De Berker, D.; Kaufmann, R.; Lecha, M.; Faergemann, J.; Kerrouche, N.; Sidou, F. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. *Br. J. Dermatol.* 2007, 157, 149–157. [PubMed]

23. Avner, S.; Nir, N.; Henri, T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of dermatophyte onychomycosis. *Dermatol. Surg.* 2014, 40, 1201–1207. [CrossRef] [PubMed]

24. Gupta, A.K. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: A randomized, evaluator-blinded study. *J. Drugs Dermatol.* JDD 2005, 4, 481–485. [CrossRef]

25. Bassiri-Jahromi, S.; Ehsani, A.H.; Mirshams-Shahshahani, M.; Jamshidi, B. A comparative evaluation of combination therapy of terbinafine and 5% amorolfine lacquer versus 5% amorolfine lacquer alone in the treatment of toenail onychomycosis. *J. Cosmet. Laser Ther.* 2013, 25, 41–46. [CrossRef] [PubMed]

26. Xu, Y.; Miao, X.; Zhou, B.; Luo, D.; Xu, Y. The efficacy of fractional carbon dioxide (CO₂) laser combined with lichenolone 1% cream for the treatment of onychomycosis: A randomized, controlled trial. *Medicine (Baltim).* 2016, 95, e5141. [CrossRef]

27. Lecha, M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. *Br. J. Dermatol.* 2003, 149, 21–26. [CrossRef] [PubMed]

28. Rigopoulos, D.; Katoulis, A.; Ioannides, D.; Georgala, S.; Kalogeromitros, D.; Karistinou, A.; Christofidou, E.; Patthamalai, P.; Tantrapornpong, P.; Suphatsathienkul, P.; Kiratiwongwan, R.; et al. Randomized controlled trial comparing long-pulsed 1064-nm Nd: YAG laser plus topical antifungal versus fractional CO₂ laser versus topical antifungal in the treatment of onychomycosis. *Dermatol. Surg.* 2013, 39, 2333–2338. [CrossRef] [PubMed]

29. Zaki, A.M.; Abdo, H.M.; Ebadah, M.A.; Ibrahim, S.M. Fractional CO₂ laser plus topical antifungal versus fractional CO₂ laser versus topical antifungal in the treatment of onychomycosis nails. *J. Dermatol. Ther.* 2020, 31, 406–409. [CrossRef] [PubMed]

30. Bonhert, K.; Dorizas, A.; Sadick, N.S. Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd: YAG laser for the treatment of onychomycosis nails. *Dermatol. Ther.* 2019, 32, 179–183. [CrossRef] [PubMed]

31. Gupta, A.K.; Cooper, E.A.; Paquet, M. Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono-and combined therapy of terbinafine and itraconazole. *J. Cutan. Med. Surg.* 2013, 17, 201–206. [CrossRef] [PubMed]

32. Arenas, R.; Fernández, G.; Dominguez, L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. *Int. J. Dermatol.* 1991, 30, 586–589. [CrossRef] [PubMed]

33. Zhang, J.; Lu, S.; Huang, H.; Li, X.; Cai, W.; Ma, J.; Xi, L. Combination therapy for onychomycosis using a fractional 2940-nm Er: YAG laser and 5% amorolfine nail lacquer. *Lasers Med. Sci.* 2016, 31, 1391–1396. [CrossRef] [PubMed]

34. Bonhert, K.; Dorizas, A.; Sadick, N.S. Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd: YAG laser for the treatment of onychomycosis nails. *Dermatol. Ther.* 2019, 32, 179–183. [CrossRef] [PubMed]

35. Bonhert, K.; Dorizas, A.; Sadick, N.S. Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd: YAG laser for the treatment of onychomycosis nails. *Dermatol. Ther.* 2019, 32, 179–183. [CrossRef] [PubMed]

36. Zhang, J.; Zhang, Y.; Qin, J.; Lu, S.; Cai, W.; Li, J.; Huang, H.; Yang, S.; Xi, L. Comparison of a fractional 2940-nm Er: YAG laser and 5% amorolfine nail lacquer plus topical antifungal versus fractional CO₂ laser versus topical antifungal in the treatment of onychomycosis. *J. Dermatol. Ther.* 2020, 19, 2333–2338. [CrossRef] [PubMed]

37. Zaki, A.M.; Abdo, H.M.; Ebadah, M.A.; Ibrahim, S.M. Fractional CO₂ laser plus topical antifungal versus fractional CO₂ laser versus topical antifungal in the treatment of onychomycosis. *Dermatol. Ther.* 2020, 33, e13155. [CrossRef] [PubMed]

38. Zhou, B.R.; Yan, L.; Permatasari, F.; Huang, H.; Li, J.; Liu, J.; Zhang, J.A.; Luo, D.; Xu, Y. The efficacy of fractional carbon dioxide (CO₂) laser combined with lichenolone 1% cream for the treatment of onychomycosis: A randomized, controlled trial. *Medicine (Baltim).* 2016, 95, e5141. [CrossRef] [PubMed]

39. Xu, Y.; Miao, X.; Zhou, B.; Luo, D. Combined oral terbinafine and long-pulsed 1064-nm Nd: YAG laser treatment is more effective for onychomycosis than either treatment alone. *Dermatol. Surg.* 2014, 40, 1201–1207. [CrossRef] [PubMed]
65. Odom, R.B.; Aly, R.; Scher, R.K.; Daniel, C.; Elewski, B.E.; Zaia, N.; DeVillez, R.; Jacko, M.; Olekag, N.; Moskovitz, B.L. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J. Am. Acad. Dermatol. 1997, 36, 231–235. [CrossRef]
66. Zhang, L.; Xu, H.; Shi, Y.; Yu, J.; Tao, Y.; Li, X. An exploration of the optimum dosage and number of cycles of itraconazole pulse therapy for severe onychomycosis. Mycoses 2018, 61, 736–742. [CrossRef]
67. Havu, V.; Brandt, H.; Heikkilä, H.; Holmlen, A.; Oksman, R.; Rantanen, T.; Saari, S.; Stubb, S.; Turjanmaa, K.; Piepponen, T. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br. J. Dermatol. 1997, 136, 230–234.
68. Elewski, B.E.; Rich, P.; Pollak, R.; Pariser, D.M.; Watanabe, S.; Senda, H.; Ieda, C.; Smith, K.; Pillai, R.; Ramakrishna, T.; et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J. Am. Acad. Dermatol. 2013, 68, 600–608. [CrossRef]
69. Tschen, E.H.; Bucko, A.D.; Oizumi, N.; Kawabata, H.; Olin, J.T.; Pillai, R. Efinaconazole solution in the treatment of toenail onychomycosis: A phase 2, multicenter, randomized, double-blind study. J. Drugs Dermatol. 2013, 12, 186–192.
70. Gupta, A.K.; Cooper, E.A. Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis. Ski. Ther. Lett. 2021, 26, 5–10. [CrossRef]
71. Jellinek, N.J.; Korotzer, A. Prognostic Factors for Complete Cure Following Treatment of Mild and Moderate Toenail Onychomycosis With Efinaconazole Topical Solution 10. J. Drugs Dermatol. JDD 2015, 14, 871–875.
72. Yang, E.J.; Lipner, S.R. Pharmacy costs of medications for the treatment of onychomycosis in the United States. J. Am. Acad. Dermatol. 2019, 81, 276–278. [CrossRef]
73. Lin, K.; Lipner, S.R. Modeling of usage and estimation of cost for efinaconazole 10% topical solution in the treatment of onychomycosis. J. Am. Acad. Dermatol. 2020, 83, 227–228. [CrossRef]
74. Wang, Y.; Lipner, S.R. Analysis of utilization, cost and, prescription trends of onychomycosis medications among medicare patients. J. Am. Acad. Dermatol. 2021, 86, 440–442. [CrossRef]
75. Nijenhuis-Rosien, L.; Kleefstra, N.; Van Dijk, P.R.; Wolfhagen, M.J.; Groenier, K.H.; Bilo, H.J.; Landman, G.W. Laser therapy for onychomycosis in patients with diabetes at risk for foot ulcers: A randomized, quadruple-blind, sham-controlled trial (LASER-1). J. Eur. Acad. Dermatol. Venereol. 2019, 33, 2143–2150. [CrossRef]
76. Waibel, J.; Wulkan, A.J.; Rudnick, A. Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis. J. Drugs Dermatol. JDD 2013, 12, 1237–1242.
77. Ortiz, A.E.; Truong, S.; Serowka, K.; Kelly, K.M. A 1320-nm Nd: YAG laser for improving the appearance of onychomycosis. Lasers Surg. Med. 2014, 40, 1356–1360. [CrossRef]
78. Yang, E.J.; Lipner, S.R. Pharmacy costs of medications for the treatment of onychomycosis in the United States. J. Am. Acad. Dermatol. 2019, 81, 276–278. [CrossRef]
79. Sabbah, L.; Gagnon, C.; Bernier, F.-E.; Maari, C. A randomized, double-blind, controlled trial evaluating the efficacy of Nd: YAG 1064 nm short-pulse laser compared with placebo in the treatment of toenail onychomycosis. J. Cutan. Med. Surg. 2017, 21, 507–512. [CrossRef]
80. Elmorsy, E.H.; Abou Khadr, N.A.; Taha, A.A.; Abdel Aziz, D.M. Long-pulsed Nd: YAG (1064 nm) laser versus Q-switched Nd: YAG (1064 nm) laser for treatment of onychomycosis. Lasers Surg. Med. 2020, 52, 621–626. [CrossRef]
81. Li, Y.; Yu, S.; Xu, J.; Zhang, R.; Zhao, J. Comparison of the efficacy of long-pulsed Nd: YAG laser intervention for treatment of onychomycosis of toenails or fingernails. J. Drugs Dermatol. JDD 2014, 13, 1258–1263.
82. El-Tatawy, R.A.; El-Nabyl, N.M.A.; El-Hawary, E.E.; Talaat, R.A.Z. A comparative clinical and mycological study of Nd:YAG laser versus topical terbinafine in the treatment of onychomycosis. J. Dermatol. Treat. 2015, 26, 461–464. [CrossRef]
83. Landsman, A.S.; Robbins, A.H.; Angelini, P.F.; Wu, C.C.; Cook, J.; Oster, M.; Bornstein, E.S. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J. Am. Podiatr. Med. Assoc. 2010, 100, 166–177.
84. Alberdi, E.; Gómez, C. Methylene blue vs. methyl aminolevulinate photodynamic therapy in the treatment of mild-to-moderate toenail onychomycosis: Short- and medium-term effects. Dermatol. Ther. 2019, 33, e14280. [CrossRef]
85. Figueiredo Souza, L.; Souza, S.; Botelho, A. Randomized controlled trial comparing photodynamic therapy based on methylene blue dye and fluconazole for toenail onychomycosis. Dermatol. Ther. 2014, 27, 43–47. [CrossRef]
86. Gupta, A.K.; Foley, K.A.; Daigle, D. Clinical trials of lasers for toenail onychomycosis: The implications of new regulatory guidance. J. Dermatol. Treat. 2017, 28, 264–270. [CrossRef]
87. Gupta, A.K.; Venkataraman, M.; Quinlan, E.M. Efficacy of lasers for the management of dermatophyte toenail onychomycosis. J. Am. Podiatr. Med. Assoc. 2021, 20, 236. [CrossRef]
88. Ma, W.; Si, C.; Carrero, L.M.K.; Liu, H.F.; Yin, X.F.; Liu, J.; Xu, Y.; Zhou, B. Laser treatment for onychomycosis: A systematic review and meta-analysis. Medicine 2019, 98, e17948. [CrossRef]
89. Drake, L.A.; Shear, N.H.; Arlette, J.P.; Cloutier, R.; Danbye, F.W.; Elewski, B.E.; Garnis-Jones, S.; Giroux, J.-M.; Gratton, D.; Gulliver, W.; et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J. Am. Acad. Dermatol. 1997, 37, 740–745. [CrossRef]
90. Goodfield, M. Short-duration therapy with terbinafine for dermatophyte onychomycosis: A multicentre trial. Br. J. Dermatol. 1992, 126, 33–35. [CrossRef]
91. Ferwerda, B.; Ferwerda, G.; Plantinga, T.; Willment, J.; van Spriel, A.; Venselaar, H.; Elbers, C.C.; Johnson, M.; Cambi, A.; Huysamen, C.; et al. Human dectin-1 deficiency and mucocutaneous fungal infections. *N. Engl. J. Med.* 2009, 361, 1760–1767. [CrossRef] [PubMed]
92. Gupta, A.K.; Simpson, F.C.; Brintnell, W.C. Do genetic mutations and genotypes contribute to onychomycosis? *Dermatology* 2014, 228, 207–210. [CrossRef] [PubMed]
93. Gupta, A.; Gover, M.; Lynde, C. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. *J. Eur. Acad. Dermatol. Venereol.* 2006, 20, 1188–1193. [CrossRef] [PubMed]
94. Vlahovic, T.C.; Joseph, W.S. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes. *J. Drugs Dermatol.* 2014, 13, 1186–1190.
95. Albreski, D.; Gross, E. The safety of itraconazole in the diabetic population. *J. Am. Podiatr. Med. Assoc.* 1999, 89, 339–345. [CrossRef]
96. Aly, R.; Winter, T.; Hall, S.; Vlahovic, T. Topical Tavaborole in the Treatment of Onychomycosis Complicated by Dermatophytoma: A Post-hoc Assessment of Phase II Subjects. *J. Drugs Dermatol. JDD* 2018, 17, 347–354.
97. Cosio, T.; Gaziano, R.; Zuccari, G.; Costanza, G.; Grelli, S.; Di Francesco, P.; Bianchi, L.; Campione, E. Retinoids in Fungal Infections: From Bench to Bedside. *Pharmaceuticals* 2021, 14, 962. [CrossRef]
98. Nasr, M.; Abd-Elhamid, N.; Abd-Allah, D.; Elkholy, B.M. Acitretin: Could It Be a New Therapeutic Player in the Field of Onychomycosis? *Mycoses* 2022, 1–9. [CrossRef]